Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes

European Journal of Haematology

Volumn 90, Issue 5, 2013, Pages 375-384

  Zhang, Zheng ^a   Li, Xiao ^a   Guo, Juan ^a   Xu, Feng ^a   He, Qi ^a   Zhao, Youshan ^a   Yang, Yujuan ^a   Gu, Shucheng ^a   Zhang, Yan ^a   Wu, Lingyun ^a   Chang, Chunkang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

Cytokines interleukins; Myelodysplastic syndromes; Th17 cells

Indexed keywords

GAMMA INTERFERON; HLA DR15 ANTIGEN; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; MESSENGER RNA; RECEPTOR SUBUNIT; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ALLELE; ANEMIA; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; KARYOTYPE; LOW RISK POPULATION; MALE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SUBUNIT; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANEMIA; BONE MARROW CELLS; FEMALE; HLA-DR SEROLOGICAL SUBTYPES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-17; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; RECEPTORS, INTERLEUKIN-17; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84876704647     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12074     Document Type: Article

References (32)

1. Li X, Wu L, Ying S, et al. Clonality investigation of morphologically dysplastic hematopoietic cells in myelodysplastic syndrome marrows. Int J Hematol 2008;87:176-83.
2. Span LF, Vierwinden G, Pennings AH, et al. Programmed cell death is an intrinsic feature of MDS progenitors, predominantly found in the cluster-forming cells. Exp Hematol 2005;33:435-42.
3. Tehranchi R, Fadeel B, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003;101:1080-6.
4. Kochenderfer JN, Kobayashi S, Wieder ED, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002;100:3639-45.
5. Wlodarski MW, Gondek LP, Nearman ZP, et al. Molecular strategies for detection and quantitation od clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome. Blood 2006;108:2632-41.
6. Calado RT. Immunologic aspects of hypoplastic myelodysplastic syndrome. Semin Oncol 2011;38:667-72.
7. Zheng Z, Qianqiao Z, Qi H, et al. In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome. Exp Hematol 2010;38:677-84.
8. Zheng Z, Feng X, Xiao L, et al. Removal of autologous activated CD4-positive T lymphocytes also results in increased colony-forming units in patients with low and intermediate-1 risk myelodysplastic syndromes. Eur J Haematol 2011;86:47-56.
9. Kondo A, Yamashita T, Tamura H, et al. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood 2010;116:1124-31.
10. Reynolds JM, Angkasekwinai P, Dong C. IL-17 family member cytokines: regulation and function in innate immunity. Cytokine Growth Factor Rev 2010;21:413-23.
11. Dong C. Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol 2006;6:329-34.
12. Weaver CT, Harrington LE, Mangan PR, et al. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677-88.
13. + T cells in malignant pleural effusion. J Immunol 2010;185:6348-54.
14. Zhang JP, Yan J, Xu J, et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009;50:980-9.
15. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-40.
16. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003;421:744-8.
17. Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis. Rheumatology 2009;48:602-6.
18. Bouchliou I, Miltiades P, Nakou E, et al. Th17 and Foxp3(+) T regulatory cell dynamics and distribution in myelodysplastic syndromes. Clin Immunol 2011;139:350-9.
19. Kordasti SY, Afzali B, Lim Z, et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009;145:64-72.
20. Valent P, Horny HP, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of themyelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007;31:727-36.
21. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.
22. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
23. Li X, Xu F, He Q, et al. Comparison of immunological abnormalities of lymphocytes in bone marrow in myelodysplastic syndrome (MDS) and aplastic anemia (AA). Intern Med 2010;49:1349-55.
24. Xiao L, Qiong L, Yan Z, et al. Experimental and clinical characteristics in myelodysplastic syndrome patients with or without HLA-DR15 allele. Hematol Oncol 2010;28:98-103.
25. Xiao L, Qi Z, Qiusheng C, et al. The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression. Am J Hematol 2012;87:26-31.
26. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 2006;108:1497-503.
27. Kerbauy DB, Deeg HJ. Apoptosis and anti-apoptotic mechanisms in the progression of MDS. Exp Hematol 2007;35:1739-46.
28. Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006;281:35603-7.
29. Kryczek I, Banerjee M, Cheng P, et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009;114:1141-9.
30. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002;100:1570-4.
31. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003;102:3025-7.
32. Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008;26:2505-11.